Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionEnsign Peak Advisors, Inc
Latest Disclosed Ownership69,647 shares
Latest Disclosed Value $ 23,044,103
Ensign Peak Advisors, Inc reports 20.22% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - Ensign Peak Advisors, Inc filed a 13F-HR form disclosing ownership of 69,647 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $19,898,148 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 57,932 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 20.22% during the quarter. The current value of the position is $18,143,044 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 69,647 11,715 20.22 23,044 0.03 0.0429
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,932 -9,801 -14.47 23,037 -25.42 0.0407
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67,733 -32,476 -32.41 30,886 -5.48 0.0507
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 100,209 19,730 24.52 32,677 50.38 0.0559
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 80,479 4,015 5.25 21,731 20.78 0.0416
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 76,464 -4,104 -5.09 17,993 -18.80 0.0320
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 80,568 7,095 9.66 22,159 24.11 0.0390
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 73,473 -8,297 -10.15 17,854 46.10 0.0326
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 81,770 -5,827 -6.65 12,221 -27.11 0.0223
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 87,597 28,373 47.91 16,767 59.86 0.0332
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 59,224 11,904 25.16 10,489 16.70 0.0224
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,320 7,745 19.57 8,988 13.37 0.0182
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,575 2,482 6.69 7,928 -10.07 0.0172
2023-02-13 2022-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 37,093 1,563 4.40 8,815 23.96 0.0199
2022-11-14 2022-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 35,530 -1,335 -3.62 7,111 32.27 0.0177
2022-08-12 2022-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 36,865 435 1.19 5,376 -9.62 0.0128
2022-05-16 2022-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 36,430 -4,330 -10.62 5,948 -13.96 0.0121
2022-02-11 2021-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 40,760 -127,839 -75.82 6,913 -78.28 0.0132
2021-11-12 2021-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 168,599 -4,144 -2.40 31,833 8.70 0.0663
2021-08-13 2021-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 172,743 4,942 2.95 29,284 23.60 0.0591
2021-05-12 2021-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 167,801 57,463 52.08 23,692 65.22 0.0509
2021-02-12 2020-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 110,338 -2,870 -2.54 14,340 -13.00 0.0325
2020-11-12 2020-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 113,208 37,241 49.02 16,483 46.50 0.0416
2020-08-12 2020-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 75,967 36,010 90.12 11,251 158.64 0.0306
2020-05-11 2020-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 39,957 35,266 751.78 4,350 705.56 0.0146
2020-02-14 2019-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 4,691 4,691 540 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.